Introduction
Primitive neuroectodermal tumors (PNET) of the cerebellum, also termed medulloblastomas (PNET/ MB) and supratentorial PNETs constitute more than 20% of all pediatric brain tumors, and are the most common malignant brain tumors in children (Pollack, 1994) . PNETs are characterized by their aggressive clinical behavior and high risk of leptomeningeal dissemination. Despite 5-year survivals for PNET/MB exceeding 80% in some studies (Packer et al., 1994) , nearly half of these patients will eventually die from progressive tumors. Accordingly, the identi®cation of new therapies remains a major goal.
Death receptors have been recently identi®ed as a subgroup of the tumor necrosis factor receptor (TNFR) superfamily with a predominant function in induction of apoptosis. These receptors are characterized by an intracellular region, called the death domain, which is required for the transmission of the apoptotic signal (Schulze-Ostho et al., 1998) . Use of death receptors to initiate apoptosis in tumor cells is a compelling therapeutic strategy. However, the clinical utility of targeting CD95 (Fas, APO-1) or TNFR1 in cancer has been limited by the severe side eects that accompany the activation of these receptors . Injection of agonistic anti-CD95 antibodies in mice causes death due primarily to liver damage caused by apoptosis of hepatocytes, which express high levels of CD95 (Nagata, 1997) . TNF injection initiates a lethal, systemic in¯ammatory response syndrome mediated by TNF activation of the transcription factor NF-kB (Vassalli, 1992) .
TNF-related apoptosis-inducing ligand (TRAIL, APO2L) is a newly identi®ed member of the tumor necrosis factor family (Wiley et al., 1995) , which induces weak activation of NF-kB compared to TNF. TRAIL predominantly induces apoptosis in transformed cell lines, however it has minimal or no toxicity against normal tissues, as examined both in vitro and in vivo in mice and in nonhuman primates . TRAIL has recently been shown to exert cytostatic or cytotoxic eects in vitro against a wide range of human tumor cells, including cell lines derived from prevalent types of cancer (e.g. carcinoma of the lung, colon, breast, prostate, malignant glioma) Rieger et al., 1998; Wiley et al., 1995) . TRAIL treatment of mice bearing human solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival .
Four high-anity TRAIL-receptors have been identi®ed to date. The agonists TRAIL-R1 (DR4) (Pan et al., 1997a) and TRAIL-R2 (DR5, KILLER) (Wu et al., 1997; Walczak et al., 1997) induce apoptosis upon binding of TRAIL. The antagonistic receptors TRAIL-R3 (DcR1, TRID) Pan et al., 1997b) and TRAIL-R4 (DcR2, TRUNDD) (Pan et al., 1998) cannot transduce the cell death signal. While their extracellular TRAIL-binding domain is homologous to that of the agonistic TRAIL receptors, their cytoplasmic domains dier remarkably. TRAIL-R3 lacks the complete intracellular portion, and the cytoplasmatic region of TRAIL-R4 contains a truncated (non-functional) cytoplasmatic death domain. The mRNAs for TRAIL-R3 and TRAIL-R4 are expressed in multiple normal tissues but less frequently in tumor cell lines Marsters et al., 1997) . Transfection experiments indicate that TRAIL-R3 and TRAIL-R4 prevent TRAIL from inducing apoptosis through TRAIL-R1 and TRAIL-R2 . Thus, it has been proposed that TRAIL-R3 and TRAIL-R4 act as decoys to inhibit the cytotoxic eect of TRAIL in normal tissues (Pan et al., 1997b) .
The caspase pathway mediates TRAIL-induced apoptosis (Mariani et al., 1997; Marsters et al., 1996) . Activation of agonistic TRAIL-R2 enables the adapter protein FADD and the caspase-8 (FLICE, MACH) to bind to the receptor. Recruitment of caspase-8 leads to its proteolytic activation, which initiates a cascade of caspases, leading to apoptosis (Bodmer et al., 2000) . The cellular FLICE inhibitory protein (cFLIP) is a recently identi®ed protein homolog to caspase-8 that lacks catalytic activity (Irmler et al., 1997) . Expression of cFLIP has been suggested to play a signi®cant role in controlling the susceptibility of tumor cells to the apoptosis-inducing eects of TRAIL (Grith et al., 1998) .
Induction of tumor cell death by direct activation of TRAIL receptors might be an attractive new therapeutic strategy in childhood PNET. In this study, we analysed eight PNET cell lines for susceptibility to TRAIL-induced apoptosis. We then examined PNET cells for expression of TRAIL receptors, caspases and cFLIP to determine whether the variable induction of apoptosis by TRAIL in PNET cells can be related to the expression of the dierent types of TRAIL receptors and/or to the expression of important intracellular signaling elements of TRAIL.
Results

Cytotoxicity of human PNET cell lines to TRAIL
Eight human PNET cell lines were assessed by MTT assay for sensitivity to TRAIL-induced cytotoxicity at a concentration of 200 ng/ml TRAIL for 24 h ( Figure  1 ). Because inhibition of protein synthesis has previously been shown to sensitize tumor cells to TRAIL (Rieger et al., 1998) , these experiments were performed in the absence or presence of cycloheximide (1 mg/ml). In the absence of cycloheximide, only one (PFSK) of eight PNET cell lines was susceptible to TRAILinduced cytotoxicity (de®ned as a survival rate of 570% compared to control cells). Co-exposure to TRAIL and cycloheximide enhanced TRAIL-induced cytotoxicity in PFSK and killed DAOY and UW228-2, whereas D341, D384, D425, D458 and CHOP707 remained resistant. Jurkat T cells served as positive control (Zhang et al., 1999) .
PFSK and DAOY cells were tested for dosedependency of TRAIL-induced cytotoxicity ( Figure  2a) . For PFSK cells, the IC 50 was 20 ng/ml TRAIL and 0.5 ng/ml TRAIL in the presence of cycloheximide. For DAOY cells, the IC 50 was 4200 ng/ml TRAIL and 12.5 ng/ml TRAIL in the presence of cycloheximide. TRAIL-induced cytotoxicity in PFSK TRAIL-induced cell death showed typical morphological features of apoptosis such as nuclear condensation and formation of nuclear bodies, as observed in phase contrast microscopy. DNA strand breaks were also observed using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TU-NEL) (data not shown). DNA fragmentation was quanti®ed using a cell death ELISA. DAOY cells showed a 7.6+0.6-fold increase in cytoplasmic histoneassociated-DNA-fragments after 24 h TRAIL (200 ng/ ml) treatment, while the increase was 3.6+0.2-fold for PFSK cells.
Expression of TRAIL and TRAIL receptors in human PNET cells
The mRNA expression of TRAIL and its agonistic (TRAIL-R1 and -R2) and antagonistic (TRAIL-R3 and -R4) receptors was assessed by semiquantitative RT ± PCR analysis ( Figure 3 ). TRAIL mRNA expression was detected only in DAOY and UW228-2. The other six evaluated PNET cell lines did not express TRAIL mRNA. All PNET cell lines expressed agonistic TRAIL-R2 at high levels, however, only three expressed TRAIL-R1, suggesting that TRAIL-R2 is the main agonistic TRAIL-receptor in PNET. All PNET cell lines expressed antagonistic TRAIL-R3, although the expression levels were highly variable. DAOY, D341 and D425 expressed low levels of TRAIL-R3. Only two of eight PNET cell lines expressed TRAIL-R4.
Since expression of antagonistic TRAIL receptors has been shown to play a role in controlling TRAILinduced apoptosis, we compared expression levels of TRAIL receptors with susceptibility to TRAIL-induced apoptosis. However, there was no apparent correlation between TRAIL receptor expression at the mRNA level and susceptibility to apoptosis. For example, the TRAIL-sensitive PFSK cells expressed antagonistic TRAIL-R3 and TRAIL-R4 at relatively high levels, whereas the TRAIL-resistant D425 cells expressed no TRAIL-R4 and relatively little TRAIL-R3 mRNA. However, the fact that mRNA expression is not necessarily followed by translation into protein has to be taken into account.
Caspase-dependency of TRAIL-induced apoptosis in PNET cells
Since caspase activation has been shown to play a role in TRAIL-induced apoptosis, we tested the susceptibility of the TRAIL-sensitive PNET cell lines to apoptosis in the presence of a pancaspase inhibitor (zVAD-fmk), together with speci®c inhibitors for caspase-8 (zIETD-fmk) and caspase-9 (zLEHD-fmk). TRAIL-induced apoptosis in TRAIL-sensitive PNET cell lines was signi®cantly blocked in the presence of zVAD-fmk and zIETD-fmk. In contrast, the caspase-9 inhibitor zLEHD-fmk did not inhibit the cytotoxic eects of TRAIL (Figure 4) . Thus, activation of caspase-8 appears to be essential for TRAIL-induced apoptosis in PNET cells, whereas activation of caspase-9 appears to be redundant. Caspase-8 activation in response to TRAIL treatment in PNET cell lines could be directly demonstrated by cleavage of the protein in a Western blot assay (data not shown).
Expression of cFLIP, caspase-8 and caspase-3 in human PNET cells
Since critical involvement of caspases in TRAILinduced apoptosis has been demonstrated before, we examined the expression pro®le of caspase-8, caspase-3 and caspase-8 homolog cFLIP, and compared cFLIP, caspase-8 and -3 expression with susceptibility to TRAIL-induced apoptosis. Semiquantitative RT ± PCR of eight PNET cell lines revealed high mRNA expression of cFLIP in seven PNET cell lines and very low levels of cFLIP in the TRAIL-resistant PNET cell line D458. Western blotting revealed cFLIP protein in all PNET cell lines. The TRAIL sensitive UW228-2 and PFSK PNET cell lines expressed high levels of cFLIP protein and the TRAIL resistant D341 and D384 PNET cell lines showed low levels of cFLIP protein, indicating that cFLIP alone is not sucient to regulate the susceptibility of PNET cells to TRAILinduced apoptosis. Caspase-3 was expressed in all PNET cell lines evaluated (data not shown). However, caspase-8 mRNA was detected in only four of eight PNET cell lines (Figure 5a ). This unexpected expression pattern of caspase-8 was examined on the protein level by Western blot analysis, revealing high caspase-8 protein levels in three of four cell lines with caspase-8 mRNA expression (Figure 5b ). Most interestingly, a clear correlation of caspase-8 expression and susceptibility to TRAIL induced apoptosis became apparent. PFSK (sensitive to TRAIL alone) and DAOY and UW228-2 (sensitive to TRAIL when exposed to cycloheximide) expressed caspase-8 mRNA and protein. The ®ve TRAIL-resistant PNET cell lines did not express caspase-8 protein.
Demethylation by 5-Aza-2'-deoxycytidine restores caspase-8 expression
The human caspase-8 gene is located on chromosome 2q33 ± 34 (Grenet et al., 1999) . Because losses of chromosome 2 are uncommon in PNET as detected by comparative genomic hybridization (Russo et al., 1999) , we hypothesized that aberrant gene methylation might lead to the loss of caspase-8 gene function in a subset of PNET cells. Therefore, we treated TRAIL-resistant D458 and CHOP707 cells with the methyltransferase inhibitor 5-aza-2'-deoxycytidine and examined caspase-8 mRNA expression by RT ± PCR, and sensitivity to TRAILinduced apoptosis by MTT assay. Interestingly, treatment with 5-aza-2'-deoxycytidine (2 mM) for 4 days resulted in restoration of caspase-8 mRNA expression (Figure 6a ), caspase-8 protein expression (Figure 6b ) and restoration of sensitivity to TRAILinduced apoptosis (Figure 6c ). These data suggest, that aberrant gene methylation may lead to caspase-8 gene silencing and resistance to TRAIL-induced apoptosis in a subset of PNET cells. However, it remains to be tested whether treatment with 5-aza-2'-deoxycytidine in¯uences also other genes involved in TRAIL-induced apoptosis.
Discussion
A majority of metastatic and most recurrent childhood PNETs are resistant to current therapeutic approaches, including high-dose chemotherapy with autologous hematopoetic stem cell rescue. Therefore, the search for additional approaches to therapy is essential. Targeting death receptors to induce apopto- Oncogene TRAIL-resistant PNET cells lack caspase-8 expression MA Grotzer et al sis in tumor cells is a novel therapeutic strategy and it has been shown that PNET cell lines are sensitive to CD95L-induced apoptosis . However, CD95 targeting in vivo has serious toxicity, which limits its clinical use. On the other hand, TRAIL induces apoptosis in DAOY PNET cells (Nakamura et al., 2000) and exerts potent antitumor activity in vivo against a range of solid tumor models without exhibiting systemic toxicity . Thus, targeting the TRAIL system may be an equally eective yet potentially safer approach of inducing apoptosis in human PNET cells. To examine whether the TRAIL system is a suitable therapeutic strategy in PNET, we tested a panel of eight PNET cell lines for susceptibility to TRAIL-induced apoptosis. We then correlated TRAIL-sensitivity with dierential expression of agonistic and antagonistic TRAIL receptors, initiator-and eector-caspases and the caspase-8 inhibitor cFLIP.
The present study shows that three of eight PNET cell lines are susceptible to TRAIL-induced apoptosis, whereas ®ve PNET cell lines are resistant. Several possible mechanisms of resistance to TRAIL-induce dell death in cancer cells have been reported, such as lack of agonistic TRAIL-receptors or enhanced expression of antagonistic TRAIL-receptors (Pan et al., 1997b; Rieger et al., 1998; Sheridan et al., 1997) . However, all PNET cell lines expressed agonistic TRAIL receptors, and resistance to TRAIL-induced apoptosis did not correlate with expression of antagonistic TRAIL receptors, suggesting additional or other regulatory mechanisms. Because TRAIL induces apoptosis in target cells in a caspasedependent fashion, we hypothesized that the resistance to TRAIL might depend on the level of expression of cFLIP, which inhibits the activation of caspase-8 (Irmler et al., 1997; Tschopp et al., 1998) , or on the level of the expression of caspases. Interestingly, all TRAIL-sensitive PNET cells expressed caspase-8 mRNA and protein, whereas none of the TRAIL-resistant cell lines expressed caspase-8 protein. These results suggest that TRAIL-sensitivity in PNET cells is primarily regulated at the intracellular level by expression of caspase-8, rather than at the receptor level. Caspase-8 knockout studies indicate that this enzyme is essential for apoptosis initiation by FAS, TNFR1 and DR3 (Varfolomeev et al., 1998) . Studies with a mutant human Jurkat T leukemia cell line that is de®cient in caspase-8 con®rm the requirement for this caspase in FASmediated apoptosis but show only partial attenuation in TNF-induced cell death (Juo et al., 1998) . The fact that TRAIL-induced apoptosis in PNET cells can be completely inhibited by the pancaspase inhibitor zVAD-fmk, and largely by the speci®c caspase-8 inhibitor zIETD-fmk suggests an essential and nonredundant role for caspase-8 in TRAIL-mediated apoptosis in PNET cells. Thus, one important TRAIL receptor signaling pathway in PNET cells is similar to that identi®ed for the CD95 receptor. It can be postulated that TRAIL-R2 signals apoptosis through the adapter protein FADD and caspase-8 with caspase-3 as one of the downstream eector caspases. PNET cells with loss of caspase-8 expression are therefore resistant to TRAIL-induced apoptosis.
Common pathways leading to loss of gene function in human cancers are alteration in the genetic code, deletion of genetic material and aberrant gene methylation. Since losses of chromosome 2 are rare in PNET, we hypothesized that hypermethylation might cause caspase-8 gene silencing. The restoration of caspase-8 mRNA and protein expression and TRAIL-sensitivity after treatment with the potent and speci®c DNA methylation inhibitor 5-aza-2'-deoxycytidine indicates that epigenetic mechanisms may be responsible for loss of caspase-8 expression in a subset of PNET cells. However, lack of caspase-8 expression might not be the sole factor responsible for TRAIL-resistance in PNET cells. TRAIL-mediated apoptosis was facilitated when protein synthesis was blocked, suggesting that the expression of anti-apoptotic proteins with a short half-life, such as cFLIP, may also be involved in the protection of PNET cells from the cytotoxic eects of TRAIL. The presence of such antiapoptotic proteins may also explain why PNET cells co-expressing TRAIL and agonistic TRAIL-receptors (DAOY, UW228-2) fail to undergo suicide or fratricide.
Induction of apoptosis via death receptors and activation of the caspase cascade has been shown to represent one possible mechanism by which chemotherapy agents act on tumor cells (Friesen et al., 1996; Fulda et al., 1997) . De®cient expression or activation of caspases may account, in part, for the failure of certain current anticancer therapies. High levels of inactive, uncleaved caspase-2 and caspase-3 have recently been associated with poor survival in patients with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) (Estrov et al., 1998; Faderl et al., 1999) . Therefore, our data may also explain the resistance of some PNET cells to drug-induced apoptosis and thus have important consequences in further attempts to manipulate tumor cell death.
Caspase-8 might be an interesting target for chemotherapy using inhibitors of DNA methylation in patients with PNET. This may help to clarify the importance of this epigenetic mechanism in PNET tumorigenesis. Treatment with recombinant soluble TRAIL, possibly in combination with inhibitors of DNA methylation, represents a promising therapeutic approach for PNET that deserves further investigation.
Materials and methods
Tumor cells
DAOY and PFSK human PNET cells and Jurkat human T cell lymphoma cells were purchased from American Type Culture Collection (Rockville, MD, USA). D341, D384, D425, D458 human PNET cells were a kind gift from Dr Henry Friedman, (Duke University, Durham, NC, USA) UW228-2 human PNET cells were a kind gift from Dr John R Silber (University of Washington, Seattle, WA, USA). DAOY, D341, D384, D425 and D458 cells were cultured in Richter's Zinc Option medium/10% FBS; PFSK, CHOP707 and Jurkat cells were cultured in RPMI/10% FBS; UW-228-2 cells in DMEM/10% FBS. All cell cultures were maintained at 378C in a humidi®ed atmosphere with 5% CO 2 .
Total RNA isolation and semiquantitative RT ± PCR After homogenization of tumor cells in guanidinium isothiocyanate-containing buer, total RNA was isolated using a silica-gel-based method according to procedures recommended by the vendor (RNeasy; Qiagen Inc., Valencia, CA, USA). RT-reactions were carried out using 1 mg of total RNA in a total volume of 20 ml, containing 150 ng random hexamers, 0.5 mM dNTPs, 10 mM dithiothreitol, 200 U SuperScriptII reverse transcriptase (all from Gibco ± BRL, Gaithersburg, MD, USA), in the reaction buer (20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl 2 ). Total RNA was denatured at 708C for 10 min and immediately chilled on ice. First-strand cDNAs were obtained after 10 min at 238C and 50 min at 428C. The reaction was terminated at 708C (15 min). Two U RNase H (Gibco ± BRL) were added to each RT reaction, followed by incubation at 378C for 20 min.
The method used for semiquantitative RT ± PCR has been described previously (Tang et al., 1999; Eggert et al., 2000) . In brief, PCR was carried out in a ®nal volume of 10 ml, containing 0.5 U Taq Gold Polymerase, 200 mM dNTPs and 0.4 mM of each primer, buer consisting of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl 2 and 1 ml of the RT-product. PCR primers were designed to bracket cDNA sequences that cross an intron-exon boundary in genomic DNA. Primer sequences for TRAIL-R1, TRAIL-R2, TRAIL-3 and TRAIL-R4 have been described and their speci®city con®rmed (Grith et al., 1998) . Primer sequences speci®c for TRAIL, human cFLIP, caspase-3, -8, and GAPD are available upon request. All PCR primers were biotinylated at their 5' ends. The samples were overlaid with mineral oil, and ampli®cation was performed on a PTC-100 Programmable Thermal Controller (MJ Research Inc., Waltham, MA, USA). The samples were initially denatured at 958C for 12 min, followed by 20 cycles with denaturation at 958C for 30 s, annealing at 558C for 30 s and extension at 728C for 90 s. The ®nal cycle was followed by a 5 min extension step at 728C. The absence of contaminants was routinely checked by RT ± PCR assays of negative control samples (H 2 O control or no reverse transcriptase added). To correct for variations in RT, PCR and chemiluminescence detection steps, the expression of the housekeeping gene GAPD was used as an internal control. Positive controls for TRAIL and TRAIL-receptors were thymus and placenta samples (Phillips et al., 1999; Wiley et al., 1995) .
Each PCR-sample (10 ml+2 ml Ficoll dye reagent) was analysed in parallel with a biotinylated molecular weight marker (Amersham, Arlington Heights, IL, USA) on a nondenaturing 6% polyacrylamide gel. DNA was electrotransferred to a nylon membrane and immobilized by UVcrosslinking. Detection of biotin-labeled DNA was performed by a chemiluminescent detection system (Tropix, Bedford, MA, USA). To provide a semiquantitative assessment of RT ± PCR-studies, we performed densitometric analysis of transcript signals using the NIH Image program (US NIH; http://rsb.info.nih.gov/nih-image/). Expression levels of the target transcripts were expressed as target/GAPD signal ratios.
Western blot analysis
Cells were lysed in Nonidet P-40 (NP 40) lysis buer (1% NP 40, 20 mM Tris pH 8.0, 137 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1 mM phenylmethylsulphonyl¯uoride, 0.15 U/ml aprotinin, 20 mM leupeptin, 1 mM sodium vanadate). Samples normalized for total protein content were separated by SDS ± PAGE, electroblotted on nitrocellulose and immunostained. Anti-caspase-8 mAb (UBI, Lake Placid, NY, USA) was used according to the manufacturer's instructions. Monoclonal antibody to cFLIP (Clone Dave-2, Alexis Corp., Lausen, Switzerland) was a kind gift from Dr J Tschopp (Lausanne, Switzerland). Detection of immunocomplexes was conducted using an ECL chemiluminescence system (Amersham Corp., Arlington Heights, IL, USA).
Reagents TRAIL (soluble human recombinant) was purchased from Upstate Biotechnology (Lake Placid, NY, USA) and used in the presence of a potentiator (mouse monoclonal IgG1) at a 1.5 mg/ml concentration, as recommended by the vendor. Cycloheximide was purchased from Sigma, and used at a concentration of 1 mg/ml, as previously described (Thomas and Hersey 1998). The pancaspase inhibitor carbobenzyloxyVal-Ala-Asp (OMe)¯uoromethyl ketone (zVAD-fmk) (Enzyme Systems Products, Livermore, CA, USA) was dissolved in DMSO, and used at a ®nal concentration of 50 mM in culture medium where indicated. The caspase-8 inhibitor zIETD-fmk and the caspase-9 inhibitor zLEHD-fmk were purchased from Calbiochem (San Diego, CA, USA). zIETDfmk and zLEHD-fmk were also O-methylated on the aspartate residue and used also at a ®nal concentration of 50 mM in culture medium where indicated. The methyltransferase inhibitor 5-aza-2'-deoxycytidine was purchased from Sigma (St. Louis, MO, USA), and used at indicated concentrations.
Cytotoxicity assay
Cell viability was quantitated using a colorimetric 3-(4,5-dimethythiazol-2-yl)-2,5-(3-diphenyl tetrazolium bromide (MTT) assay (Sigma, St. Louis, MO, USA) according to procedures previously described (Mosmann, 1983) . Brie¯y, 100 ml of target cell suspension (2610 4 cells) were added to each well of 96-well microtiter plates, and each plate was incubated at 378C in a humidi®ed 5% CO 2 atmosphere. Following incubation, 10 ml of MTT working solution were added to each culture well, and the cultures were incubated for 4 h at 378C in a humidi®ed 5% CO 2 atmosphere. Each condition was performed in triplicate. The absorbance values of each well were measured with a microculture plate reader at 570 nm. The percentage cytotoxicity was calculated using the following formula: percentage cytotoxicity=(absorbance of experimental wells/absorbance of control wells)6100.
Apoptosis
Apoptotic cells were characterized by the Terminal deoxynucleotidyl Transferase (TdT)-mediated dUTP nick-End Labeling (TUNEL) method (Gavrieli et al., 1992) . In brief, target cells incubated in chamber slides (Fisher; Pittsburgh, PA, USA) were washed with PBS and ®xed in 4% methanol in PBS for 20 min at 7208C. Cells were incubated in a humidi®ed chamber at 378C for 60 min in 100 ml reaction solution containing 0.5 ml of TdT enzyme, 10 ml of 56TdT reaction buer, and 1 ml of¯uorescence-12-dUTP (all from Promega; Madison, WI, USA). Slides were washed in PBS and incubated for 15 min at room temperature in 0.15 mg/ml DAPI to counterstain cell nuclei. Cells were visualized bȳ uorescence microscopy. A photometric enzyme-immunoassay (Cell Death Detection ELISA; Boehringer Mannheim, Indianapolis, IN, USA) was used for the quantitative determination of cytoplasmic histone-associated-DNA-fragments after TRAIL-induced cell death. Brie¯y, cell lysates of control and TRAIL-treated cells (10 4 cells) were placed into a streptavidin-coated microtiterplate. Subsequently, a mixture of biotin-labeled monoclonal histone antibody and peroxidase-conjugated monoclonal DNA antibody were added and incubated for 2 h. After removal of unbound antibodies by washing, the amount of nucleosomes was quanti®ed photometrically by the peroxidase retained in the immunocomplex with 2,2'-Azino-di[3-ethylbenzthiazolin-sulfonat]) as substrate. 
